Mallinckrodt Hosp patents expiration
1. Inomax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873359 | MALLINCKRODT HOSP | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jan, 2013
(11 years ago) | |
| US5485827 | MALLINCKRODT HOSP | Methods and devices for treating plumonary vasoconstriction and asthma |
Jan, 2013
(11 years ago) | |
|
US5873359 (Pediatric) | MALLINCKRODT HOSP | Methods and devices for treating pulmonary vasoconstriction and asthma |
Jul, 2013
(10 years ago) | |
|
US5485827 (Pediatric) | MALLINCKRODT HOSP | Methods and devices for treating plumonary vasoconstriction and asthma |
Jul, 2013
(10 years ago) | |
| US5558083 | MALLINCKRODT HOSP | Nitric oxide delivery system |
Nov, 2013
(10 years ago) | |
|
US5558083 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery system |
May, 2014
(9 years ago) | |
| US5752504 | MALLINCKRODT HOSP | System for monitoring therapy during calibration |
Dec, 2016
(7 years ago) | |
| US5732693 | MALLINCKRODT HOSP | Pause control of nitric oxide therapy |
Dec, 2016
(7 years ago) | |
| US6125846 | MALLINCKRODT HOSP | Purge system for nitric oxide administration apparatus |
May, 2017
(6 years ago) | |
|
US5732693 (Pediatric) | MALLINCKRODT HOSP | Pause control of nitric oxide therapy |
Jun, 2017
(6 years ago) | |
|
US5752504 (Pediatric) | MALLINCKRODT HOSP | System for monitoring therapy during calibration |
Jun, 2017
(6 years ago) | |
|
US6125846 (Pediatric) | MALLINCKRODT HOSP | Purge system for nitric oxide administration apparatus |
Nov, 2017
(6 years ago) | |
| US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
| US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(5 years from now) | |
| US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(5 years from now) | |
| US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
| US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(5 years from now) | |
|
US8293284 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(5 years from now) | |
|
US8282966 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(5 years from now) | |
|
US8431163 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(5 years from now) | |
|
US8795741 (Pediatric) | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(5 years from now) | |
|
US8846112 (Pediatric) | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(5 years from now) | |
| US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US9295802 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US9408993 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US9265911 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
|
US9295802 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US9408993 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
|
US8776795 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US8776794 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
|
US9265911 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US8573210 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
|
US8291904 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
|
US8573209 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
| US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(9 years from now) | |
|
US9279794 (Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(10 years from now) | |
| US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(12 years from now) | |
|
US9770570 (Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-167) | Oct 09, 2018 |
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: Prevention or treatment of reversible vasoconstriction by the inhalation of nitric oxide with an oxygen containing gas; A method of providing a predetermined concentration of nitric oxide to a patient...
Dosage: GAS;INHALATION
INOMAX family patents
2. Ofirmev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6028222 | MALLINCKRODT HOSP | Stable liquid paracetamol compositions, and method for preparing same |
Aug, 2017
(6 years ago) | |
|
US6028222 (Pediatric) | MALLINCKRODT HOSP | Stable liquid paracetamol compositions, and method for preparing same |
Feb, 2018
(6 years ago) | |
| US6992218 | MALLINCKRODT HOSP | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
Jun, 2021
(2 years ago) | |
|
US6992218 (Pediatric) | MALLINCKRODT HOSP | Method for obtaining aqueous formulations of oxidation-sensitive active principles |
Dec, 2021
(2 years ago) | |
| US9610265 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| US9987238 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
| US10383834 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(4 years from now) | |
|
US9987238 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
|
US9610265 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
| US9399012 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Sep, 2031
(7 years from now) | |
|
US9399012 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-196) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Product(NP) | Nov 02, 2013 |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate t...
Dosage: SOLUTION;INTRAVENOUS
OFIRMEV family patents